EMA 401 administered as single ascending doses ranging from 10-100mg in male volunteers

Trial Profile

EMA 401 administered as single ascending doses ranging from 10-100mg in male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2012

At a glance

  • Drugs EMA 401 (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Adverse reactions
  • Sponsors Spinifex Pharmaceuticals
  • Most Recent Events

    • 19 Sep 2012 New trial record
    • 31 Aug 2012 Results presented at the 14th World Congress on Pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top